Form 4 for MBX MBX Biosciences, Inc.
Accepted 2026-08-04 08:50:51 ET · period of report 2026-08-03 · accession 0001193125-26-331639 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-04 08:50 | 2026-08-03 | MBX | Hoerter Steven L. | Pres, CEO, Dir | A - Grant | $0.00 | +71.0K | 82.9K | +595% | $0 |
| D | 2026-08-04 08:50 | 2026-08-03 | MBX | Hoerter Steven L. | Pres, CEO, Dir | A - Grant | $0.00 | +331.0K | 331.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-03 | A | A | 71,000 | $0.00 | 82,938 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date. |
| 2 | Derivative | Stock option (right to buy) | 2026-08-03 | A | A | 331,000 | $0.00 | 331,000 | D | $64.41 · — to 2036-08-03 | 331,000 Common Stock | (F3) The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date. |